GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Starpharma Holdings Ltd (OTCPK:SPHRF) » Definitions » Short-Term Debt

Starpharma Holdings (Starpharma Holdings) Short-Term Debt : $0.52 Mil (As of Dec. 2023)


View and export this data going back to 2011. Start your Free Trial

What is Starpharma Holdings Short-Term Debt?

Starpharma Holdings's Short-Term Debt for the quarter that ended in Dec. 2023 was $0.52 Mil.

Starpharma Holdings's quarterly Short-Term Debt increased from Dec. 2022 ($3.18 Mil) to Jun. 2023 ($3.21 Mil) but then declined from Jun. 2023 ($3.21 Mil) to Dec. 2023 ($0.52 Mil).

Starpharma Holdings's annual Short-Term Debt stayed the same from Jun. 2021 ($0.00 Mil) to Jun. 2022 ($0.00 Mil) but then increased from Jun. 2022 ($0.00 Mil) to Jun. 2023 ($3.21 Mil).


Starpharma Holdings Short-Term Debt Historical Data

The historical data trend for Starpharma Holdings's Short-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Starpharma Holdings Short-Term Debt Chart

Starpharma Holdings Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
Short-Term Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - 3.21

Starpharma Holdings Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Short-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.57 - 3.18 3.21 0.52

Starpharma Holdings Short-Term Debt Explanation

Short-Term Debt represents the total amount of Long-Term Debt such as bank loans and commercial paper, which is due within one year.


Starpharma Holdings Short-Term Debt Related Terms

Thank you for viewing the detailed overview of Starpharma Holdings's Short-Term Debt provided by GuruFocus.com. Please click on the following links to see related term pages.


Starpharma Holdings (Starpharma Holdings) Business Description

Traded in Other Exchanges
Address
4-6 Southampton Crescent, Abbotsford, Melbourne, VIC, AUS, 3067
Starpharma Holdings Ltd is an Australia-based company engaged in the research, development, and commercialization of dendrimer products for pharmaceutical, life science, and other applications. It focuses on the development of VivaGel for the management and prevention of bacterial vaginosis and as a condom coating and VIRALEZE an antiviral nasal spray.

Starpharma Holdings (Starpharma Holdings) Headlines